We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Optimizing the Treatment Continuum With a Molecular-Based Approach in HER2+ GI Cancers
June 28, 2024
13:15 - 14:15 CEST
Josep Tabernero, MD, PhD
Sara Lonardi, MD
Zev A. Wainberg, MD
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
Nabil F. Saba, MD, FACP
Barbara Burtness, MD
Immune Checkpoint Therapy for Patients With Recurrent or Metastatic HNSCC
Overcoming Barriers to Equitable Care in HNSCC
Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC
Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens
Managing Immune-Related Adverse Events With Immunotherapies
First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
Allison Betof Warner, MD, PhD
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
Future Directions: Targeting LAG-3 in Melanoma Treatment
Hussein Tawbi, MD, PhD
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
Leveraging LAG-3: Innovative Immunotherapy Combinations for First-Line Metastatic Melanoma Treatment
Analyzing Key Data from LAG-3 Combinations in the Treatment of Metastatic Melanoma
Patient Case: Tailoring First-Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status
Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education